What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
Umberto Vitolo spends much of his time researching Internal medicine, Surgery, Gastroenterology, Lymphoma and Follicular lymphoma.
Internal medicine is often connected to Oncology in his work.
His studies in Gastroenterology integrate themes in fields like Survival rate, CHOP, Neutropenia, Peripheral T-cell lymphoma and Rituximab.
His Lymphoma research integrates issues from Stage and Positron emission tomography, Nuclear medicine.
The various areas that he examines in his Follicular lymphoma study include Mantle cell lymphoma, Non-Hodgkin's lymphoma and B cell.
His research in Diffuse large B-cell lymphoma intersects with topics in Testicular Involvement and Hazard ratio.
His most cited work include:
- Follicular lymphoma international prognostic index. (1297 citations)
- Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study (648 citations)
- Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study (453 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Surgery, Oncology, Rituximab and Lymphoma.
His Internal medicine study frequently involves adjacent topics like Gastroenterology.
His studies deal with areas such as Hematology, Mantle cell lymphoma and Salvage therapy as well as Oncology.
His Rituximab research is multidisciplinary, incorporating perspectives in CHOP and Fludarabine.
His research on Lymphoma also deals with topics like
- Nuclear medicine which is related to area like Radiology,
- Positron emission tomography and ABVD most often made with reference to Stage.
His Follicular lymphoma research is multidisciplinary, incorporating elements of Randomized controlled trial and Minimal residual disease.
He most often published in these fields:
- Internal medicine (75.20%)
- Surgery (37.20%)
- Oncology (36.79%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (75.20%)
- Oncology (36.79%)
- Diffuse large B-cell lymphoma (24.39%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Oncology, Diffuse large B-cell lymphoma, Lymphoma and Rituximab.
His Internal medicine study frequently draws connections between adjacent fields such as Gastroenterology.
His study in Oncology is interdisciplinary in nature, drawing from both Refractory, Chemoimmunotherapy, Hematology, Ibrutinib and Salvage therapy.
His Diffuse large B-cell lymphoma study also includes fields such as
-
Mantle cell lymphoma and Locus most often made with reference to Cancer research,
-
Clinical trial, which have a strong connection to Family medicine.
The study incorporates disciplines such as Cyclophosphamide, Progression-free survival, Chemotherapy, Bortezomib and B cell in addition to Lymphoma.
His Rituximab study also includes
-
Vincristine which is related to area like Prednisone and International Prognostic Index,
-
Hazard ratio which intersects with area such as Randomized controlled trial and Surgery.
Between 2016 and 2021, his most popular works were:
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma (186 citations)
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (182 citations)
- Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. (123 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
Internal medicine, Oncology, Diffuse large B-cell lymphoma, Rituximab and Gastroenterology are his primary areas of study.
Umberto Vitolo studied Internal medicine and Surgery that intersect with Meta-analysis.
His research integrates issues of Hematology, Salvage therapy, Ibrutinib and Chemoimmunotherapy in his study of Oncology.
He has included themes like Cell of origin, CHOP, Lenalidomide and Gene expression profiling in his Diffuse large B-cell lymphoma study.
His Rituximab research is multidisciplinary, relying on both Vincristine, Progression-free survival and Hazard ratio.
His research investigates the connection between Gastroenterology and topics such as Mitoxantrone that intersect with problems in Hematopoietic stem cell transplantation and Fludarabine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
